Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IBUPROFEN AND FAMOTIDINE vs ACULAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever. Famotidine is a histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking histamine at H2 receptors on gastric parietal cells.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
Relief of signs and symptoms of rheumatoid arthritis and osteoarthritis,Management of ankylosing spondylitis,Dysmenorrhea,Mild to moderate pain,Reduction of fever,Off-label: Migraine, gout, acute musculoskeletal pain
Treatment of postoperative inflammation in patients who have undergone cataract extraction,Relief of ocular itching due to seasonal allergic conjunctivitis
One tablet (ibuprofen 800 mg/famotidine 26.6 mg) orally three times daily.
One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.
Ibuprofen: Terminal half-life 2-4 hours (normal renal function); prolonged to 3-6 hours in elderly or hepatic impairment. Famotidine: Terminal half-life 2.5-3.5 hours (normal renal function); extended to >20 hours in severe renal impairment (Cr Cl <10 m L/min).
Terminal half-life: 1.8 hours (ketorolac tromethamine); clinical context: short half-life supports dosing every 6 hours for acute pain, but prolonged in elderly or renal impairment (↑ to 5-6 hours, thus dose reduction required).
Ibuprofen is primarily metabolized by CYP2C9 and CYP2C8. Famotidine is minimally metabolized in the liver (30-35%) via oxidative pathways; the remainder is excreted unchanged in urine.
Hepatic metabolism primarily via cytochrome P450 2C9 (CYP2C9).
Ibuprofen: Renal excretion of metabolites (90%) and unchanged drug (<10%); biliary/fecal (minor). Famotidine: Renal excretion of unchanged drug (65-70%); metabolites (25-30%); biliary/fecal (minor).
Renal: ~80% as unchanged drug and glucuronide conjugates; biliary/fecal: ~20%
Ibuprofen: >99% bound to albumin (mostly). Famotidine: 15-20% bound to plasma proteins (albumin).
99% bound; primary binding protein: albumin.
Ibuprofen: 0.1-0.2 L/kg (low, reflects high protein binding and limited tissue distribution). Famotidine: 1.1-1.4 L/kg (suggests extensive extravascular distribution).
0.11-0.25 L/kg; clinical meaning: low Vd indicates primarily confined to extracellular compartment (plasma and interstitial fluid), minimal tissue penetration.
Ibuprofen: Oral: 80-100% (well absorbed with food causing slight delay). Famotidine: Oral: 40-50% (first-pass metabolism; reduced with food).
Ophthalmic: ~2% systemic absorption after topical instillation (due to corneal permeability and nasolacrimal drainage); oral formulation not used for Acular (ophthalmic only).
Contraindicated if Cr Cl < 30 m L/min. For Cr Cl 30-49 m L/min, reduce famotidine dose by 50% (not possible with fixed combination; use alternative therapy).
No dosage adjustment required for renal impairment.
No specific dose adjustment for Child-Pugh A or B; avoid in severe hepatic impairment (Child-Pugh C) due to ibuprofen component.
No dosage adjustment required for hepatic impairment.
Not established for combination; ibuprofen 5-10 mg/kg/dose (max 400 mg) q6-8h as separate agent; famotidine 0.5 mg/kg/dose (max 20 mg) q12h for pediatric use.
Safety and efficacy in pediatric patients have not been established; use not recommended.
Start at lowest effective dose; monitor renal function; avoid if Cr Cl < 30 m L/min; increased risk of GI bleeding and renal impairment.
No specific dosage adjustment required; use same dosing as for younger adults.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
No FDA boxed warning.
Cardiovascular risk: Increased risk of serious cardiovascular thrombotic events. Gastrointestinal risk: Serious GI adverse events including bleeding, ulceration, and perforation. Renal toxicity: Monitor renal function. Hepatic effects: Elevation of liver enzymes. Anaphylactoid reactions: Bronchospasm in aspirin-sensitive asthma. Hypertension: Can worsen blood pressure control. Fluid retention and edema.
May increase bleeding time due to inhibition of platelet aggregation; use with caution in patients with known bleeding tendencies or those receiving other medications that may prolong bleeding time.,May cause corneal effects including keratitis and corneal thinning; discontinue if corneal epithelial breakdown occurs.,Use with caution in patients with prior sensitivity to aspirin, phenylacetic acid derivatives, or other NSAIDs.,May delay wound healing or exacerbate infections; avoid use in patients with active epithelial herpes simplex keratitis.
History of allergic reaction to ibuprofen, famotidine, or any other NSAID. History of aspirin-sensitive asthma. Coronary artery bypass graft (CABG) surgery. Active peptic ulcer disease or GI bleeding. Advanced renal disease. Pregnancy at 30 weeks gestation and later (risk of premature closure of ductus arteriosus).
Hypersensitivity to ketorolac tromethamine or any component of the formulation,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Active epithelial herpes simplex keratitis,Late pregnancy (third trimester) due to risk of premature closure of ductus arteriosus
Avoid alcohol; increases GI bleeding risk. No other significant food interactions. Take with food or milk to reduce gastric irritation.
No known food interactions. Avoid alcohol if concomitant oral NSAIDs are used due to increased risk of gastrointestinal bleeding, but this is not specific to ophthalmic use.
First trimester: Ibuprofen is associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Famotidine is generally considered low risk, but limited data. Second trimester: Ibuprofen use is linked to fetal renal dysfunction and oligohydramnios; famotidine appears safe. Third trimester: Ibuprofen is contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal pulmonary hypertension; famotidine has no known fetal risks.
Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairment in the third trimester. First and second trimester use should be avoided unless clearly needed. The potential benefits should be weighed against the risks.
Ibuprofen: Excretion into breast milk is low (M/P ratio 0.007-0.24); considered compatible with breastfeeding. Famotidine: Excreted in breast milk (M/P ratio approximately 0.25-0.71); infant exposure is low; generally acceptable with caution. Combined use: Limited data; monitor infant for gastrointestinal effects.
Ketorolac is excreted in human milk at low levels. The M/P ratio is not well defined. Due to potential adverse effects in nursing infants, caution is advised. Use only if clearly indicated and consider alternative agents.
Ibuprofen: No standard dose adjustment; avoid in third trimester. Famotidine: No dose adjustment required. Combined product: Avoid in third trimester; use lowest effective dose and shortest duration in first/second trimester.
No specific dose adjustments are recommended for pregnancy; however, use the lowest effective dose for the shortest duration due to potential fetal risks. Physiological changes in pregnancy (increased volume of distribution, renal clearance) may alter pharmacokinetics, but no formal studies justify dose modification.
Ibuprofen and famotidine combination tablet (Duexis) is used for osteoarthritis and rheumatoid arthritis to reduce GI ulcer risk. Do not exceed 800 mg ibuprofen per dose or 3200 mg per day. Famotidine component provides gastric protection; additional acid suppression not needed. Avoid in advanced renal disease, active GI bleeding, or COX-2 inhibitor allergy. Monitor renal function, BP, and signs of GI bleeding. Dual COX/5-LOX inhibition by ibuprofen raises cardiovascular thrombotic risk; use lowest effective dose.
ACULAR (ketorolac tromethamine ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) used for ocular inflammation. Avoid concomitant use with other NSAIDs or corticosteroids due to increased risk of corneal adverse events. Use with caution in patients with bleeding disorders or those on anticoagulants, as it may increase bleeding tendency. Monitor for corneal toxicity, especially in patients with compromised corneal integrity. Ensure proper storage at room temperature and discard if solution changes color or becomes cloudy.
Take with food or milk to reduce stomach upset.,Do not take more than 3 tablets per day (each tablet contains 800 mg ibuprofen).,May cause drowsiness or dizziness; avoid driving if affected.,Report black/tarry stools, vomiting blood, chest pain, or leg swelling immediately.,Avoid alcohol and other NSAIDs (e.g., aspirin, naproxen) while taking this medication.,Inform all healthcare providers you are taking this drug, especially before surgery.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1 minute after instillation to reduce systemic absorption.,Do not use while wearing soft contact lenses, as the preservative may be absorbed.,Report any signs of corneal problems such as pain, redness, or vision changes immediately.,Use exactly as prescribed and do not share the medication with others.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IBUPROFEN AND FAMOTIDINE vs ACULAR, answered by our medical review team.
IBUPROFEN AND FAMOTIDINE is a NSAID that works by Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever. Famotidine is a histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking histamine at H2 receptors on gastric parietal cells.. ACULAR is a NSAID Ophthalmic that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IBUPROFEN AND FAMOTIDINE and ACULAR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IBUPROFEN AND FAMOTIDINE is: One tablet (ibuprofen 800 mg/famotidine 26.6 mg) orally three times daily.. The standard adult dose of ACULAR is: One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IBUPROFEN AND FAMOTIDINE and ACULAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IBUPROFEN AND FAMOTIDINE is classified as Category D/X. First trimester: Ibuprofen is associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Famotidine is generally considered low ri. ACULAR is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairm. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.